Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant

Acta Oto-Laryngologica

Volumn 117, Issue 4, 1997, Pages 614-617

  Ferguson, E A ^a   Eccles, R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Common cold; Nasal decongestant; Nitric oxide; Nose; Oxymetazoline

Indexed keywords

DECONGESTIVE AGENT; NITRIC OXIDE; OXYMETAZOLINE;

ADULT; ARTICLE; CHEMOLUMINESCENCE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; FEMALE; GAS ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHINOMANOMETRY; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION;

EID: 0030837186     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.3109/00016489709113447     Document Type: Article

References (14)

1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
2. Vallance P, Collier J. Biology and clinical relevance of nitric oxide. BMJ 1994; 309: 453-7.
3. Croen KD. Evidence for an antiviral effect of nitric oxide. J Clin Invest 1993; 91: 2446-52.
4. Karupiah G, Xie Q, Buller RML, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferon induced nitric oxide synthase. Science 1993; 261: 1445-8.
5. Kharitonov SA, Yates D, Barnes PJ. Increased nitric-oxide in exhaled air of normal subjects with upper respiratory tract infections. Eur Respir J 1995; 8: 295-7.
6. Lundberg JON, Weitzberg E, Nordvall SL, Kuylenstierna R, Lundberg JM, Alving K. Primarily nasal origin of exhaled nitric oxide and absence in Kartagner's syndrome. Eur Respit J 1994; 7: 1501-4.
7. Schedin U, Frostell C, Persson MG, Jakobsson J, Andersson G, Gustafsson LE. Contribution from upper and lower airways to exhaled endogenous nitric oxide in humans. Acta Anaesthesiol Scand 1995; 39: 327-32.
8. Lundberg JON, Farkas-Szallasi T, Weitzberg E, et al. High nitric oxide production in human paranasal sinuses. Nat Med 1995; 1: 370-3.
9. Lundberg JON. Airborne nitric oxide: Inflammatory marker and aerocrine messenger in man. Acta Physiol Scand 1996; Suppl 633: 1-27.
10. Giraud GD, Nejadnik B, Kimberly B, Holden WE. Effects of air-flow, temperature or a topical vasoconstrictor on nasal nitric oxide release. FASEB J 1995; 9 (3 Part 1): A 326.
11. Rinder J. Sensory neuropeptides and nitric oxide in nasal vascular regulation. Acta Physiol Scand 1996; Suppl 632: 1-45.
12. Bende M, Loth S. Vascular effects of topical oxymetazoline on human nasal mucosa. J Laryngol Otol 1986; 100: 285-8.
13. Roithmann R, Cole P. Acoustic rhinometry in the evaluation of nasal obstruction. Laryngoscope 1995; 105: 275-81.
14. Furukawa K, Harrison D, Saleh D, Shennib H, Chagnon FP, Giaid A. Expression of nitric oxide synthase in the human nasal mucosa. Am J Respir Crit Care Med 1996; 153: 847-50.